<?xml version="1.0" encoding="UTF-8"?>
<Label drug="intelence" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    6 ADVERSE REACTIONS

  The following adverse reactions are described in greater detail in other sections:



 *  Severe skin and hypersensitivity reactions [ see  Warnings and Precautions (5.1)   ]. 
      EXCERPT:   The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy. (  6.1  )
 

 The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea. (  6.2  )



   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Products, LP at 1-800-JANSSEN    (1-800-526-7736) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  



 

  6.1 Clinical Trials Experience: Adults

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.



 The safety assessment is based on all data from 1203 subjects in the Phase 3 placebo-controlled trials, TMC125-C206 and TMC125-C216, conducted in antiretroviral treatment-experienced HIV-1-infected adult subjects, 599 of whom received INTELENCE  (r)  (200 mg twice daily). In these pooled trials, the median exposure for subjects in the INTELENCE  (r)  arm and placebo arm was 52.3 and 51.0 weeks, respectively. Discontinuations due to adverse drug reactions (ADRs) were 5.2% in the INTELENCE  (r)  arm and 2.6% in the placebo arm.



 The most frequently reported ADR at least Grade 2 in severity was rash (10.0%). Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ]. A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving INTELENCE  (r)  discontinued due to rash. In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4. Rash generally resolved within 1 to 2 weeks on continued therapy. The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash &gt;= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ]. Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.



     Common Adverse Reactions  



 Clinical ADRs of moderate intensity or greater (greater than or equal to Grade 2) and reported in at least 2% of subjects treated with INTELENCE  (r)  and occurring at a higher rate compared to placebo (excess of 1%) are presented in Table 1. Laboratory abnormalities considered ADRs are included in Table 2.



 Table 1: Treatment-Emergent Adverse ReactionsIncludes adverse reactions at least possibly, probably, or very likely related to the drug. of at least Moderate IntensityIntensities are defined as follows: Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating with inability to work or do usual activity). (Grades 2 to 4) in at least 2% of Adult Subjects in the INTELENCE(r) Treatment Groups and at a higher rate compared to placebo (excess of 1%) 
 System Organ Class,Preferred Term,%  Pooled TMC125-C206 and TMC125-C216 Trials   
 INTELENCE  (r)  + BRN=599                  Placebo + BRN=604            
  
 N=total number of subjects per treatment group, BR=background regimen   
  
     Nervous System Disorders                                            
     Peripheral neuropathy                          4%                                 2%                   
     Skin and Subcutaneous Tissue Disorders                                         
     Rash                                          10%                                 3%                   
             Less Common Adverse Reactions  
 

 Treatment-emergent ADRs occurring in less than 2% of subjects (599 subjects) receiving INTELENCE  (r)  and of at least moderate intensity (greater than or equal to Grade 2) are listed below by body system:



   Cardiac Disorders  : myocardial infarction, angina pectoris, atrial fibrillation



   Ear and Labyrinth Disorders  : vertigo



   Eye Disorders  : blurred vision



   Gastrointestinal Disorders  : gastroesophageal reflux disease, flatulence, gastritis, abdominal distension, pancreatitis, constipation, dry mouth, hematemesis, retching, stomatitis



   General Disorders and Administration Site Conditions  : sluggishness



   Hematologic Disorders  : hemolytic anemia



   Hepatobiliary Disorders  : hepatic failure, hepatomegaly, cytolytic hepatitis, hepatic steatosis, hepatitis



   Immune System Disorders  : drug hypersensitivity, immune reconstitution syndrome



   Metabolism and Nutrition Disorders  : diabetes mellitus, anorexia, dyslipidemia



   Nervous System Disorders  : paraesthesia, somnolence, convulsion, hypoesthesia, amnesia, syncope, disturbance in attention, hypersomnia, tremor



   Psychiatric Disorders  : anxiety, sleep disorders, abnormal dreams, confusional state, disorientation, nervousness, nightmares



   Renal and Urinary Disorders:  acute renal failure



   Reproductive System and Breast Disorders  : gynecomastia



   Respiratory,Thoracic and Mediastinal Disorders  : exertional dyspnea, bronchospasm



   Skin and Subcutaneous Tissue Disorders  : night sweats, lipohypertrophy, prurigo, hyperhidrosis, dry skin, swelling face



 Additional ADRs of at least moderate intensity observed in other trials were acquired lipodystrophy, angioneurotic edema, erythema multiforme and haemorrhagic stroke, each reported in no more than 0.5% of subjects.



     Laboratory Abnormalities in Treatment-Experienced Patients  



 Selected Grade 2 to Grade 4 laboratory abnormalities that represent a worsening from baseline observed in adult subjects treated with INTELENCE  (r)  are presented in Table 2.



 Table 2: Selected Grade 2 to 4 Laboratory Abnormalities Observed in Treatment-Experienced Subjects 
                                                         Pooled TMC125-C206 and TMC125-C216 Trials   
 Laboratory ParameterPreferred Term,%    DAIDS Toxicity Range    INTELENCE  (r)  + BRN=599     Placebo + BRN=604       
  
 ULN=Upper Limit of Normal, BR=background regimen   
  
   GENERAL BIOCHEMISTRY                                                                                       
   Pancreatic amylase                                                                                         
 Grade 2                            &gt; 1.5-2 * ULN                   7%                        8%              
 Grade 3                             &gt; 2-5 * ULN                    7%                        8%              
 Grade 4                              &gt; 5 * ULN                     2%                        1%              
   Lipase                                                                                                     
 Grade 2                            &gt; 1.5-3 * ULN                   4%                        6%              
 Grade 3                             &gt; 3-5 * ULN                    2%                        2%              
 Grade 4                               &gt; 5*ULN                      1%                       &lt; 1%             
   Creatinine                                                                                                 
 Grade 2                           &gt; 1.4-1.8 * ULN                  6%                        5%              
 Grade 3                           &gt; 1.9-3.4 * ULN                  2%                        1%              
 Grade 4                             &gt; 3.4 * ULN                    0%                       &lt; 1%             
   HEMATOLOGY                                                                                                 
   Decreased hemoglobin                                                                                       
 Grade 2                              90-99 g/L                     2%                        4%              
 Grade 3                              70-89 g/L                    &lt; 1%                      &lt; 1%             
 Grade 4                               &lt; 70 g/L                    &lt; 1%                      &lt; 1%             
   White blood cell count                                                                                     
 Grade 2                         1,500-1,999/mm  3                  2%                        3%              
 Grade 3                         1,000-1,499/mm  3                  1%                        4%              
 Grade 4                           &lt; 1,000/mm  3                    1%                       &lt; 1%             
   Neutrophils                                                                                                
 Grade 2                           750-999/mm  3                    5%                        6%              
 Grade 3                           500-749/mm  3                    4%                        4%              
 Grade 4                            &lt; 500/mm  3                     2%                        3%              
   Platelet count                                                                                             
 Grade 2                        50,000-99,999/mm  3                 3%                        5%              
 Grade 3                        25,000-49,999/mm  3                 1%                        1%              
 Grade 4                           &lt; 25,000/mm  3                  &lt; 1%                      &lt; 1%             
   LIPIDS AND GLUCOSE                                                                                         
   Total cholesterol                                                                                          
 Grade 2                       &gt; 6.20-7.77 mmol/L240-300 mg/dL            20%                       17%              
 Grade 3                       &gt; 7.77 mmol/L&gt; 300 mg/dL             8%                        5%              
   Low density lipoprotein                                                                                    
 Grade 2                       4.13-4.9 mmol/L160-190 mg/dL            13%                       12%              
 Grade 3                       &gt; 4.9 mmol/L&gt; 190 mg/dL              7%                        7%              
   Triglycerides                                                                                              
 Grade 2                       5.65-8.48 mmol/L500 -750 mg/dL             9%                        7%              
 Grade 3                       8.49-13.56 mmol/L751 - 1200 mg/dL             6%                        4%              
 Grade 4                       &gt; 13.56 mmol/L&gt; 1200 mg/dL             4%                        2%              
   Elevated glucose levels                                                                                    
 Grade 2                       6.95-13.88 mmol/L161-250 mg/dL            15%                       13%              
 Grade 3                       13.89-27.75 mmol/L251 - 500 mg/dL             4%                        2%              
 Grade 4                       &gt; 27.75 mmol/L&gt; 500 mg/dL             0%                       &lt; 1%             
   HEPATIC PARAMETERS                                                                                         
   Alanine amino transferase                                                                                   
 Grade 2                             2.6-5 * ULN                    6%                        5%              
 Grade 3                             5.1-10 * ULN                   3%                        2%              
 Grade 4                              &gt; 10 * ULN                    1%                       &lt; 1%             
   Aspartate amino transferase                                                                                   
 Grade 2                             2.6-5 * ULN                    6%                        8%              
 Grade 3                             5.1-10 * ULN                   3%                        2%              
 Grade 4                              &gt; 10 * ULN                   &lt; 1%                      &lt; 1%             
              Patients co-infected with hepatitis B and/or hepatitis C virus  
 

 In Phase 3 trials TMC125-C206 and TMC125-C216, 139 subjects (12.3%) with chronic hepatitis B and/or hepatitis C virus co-infection out of 1129 subjects were permitted to enroll. AST and ALT abnormalities occurred more frequently in hepatitis B and/or hepatitis C virus co-infected subjects for both treatment groups. Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects. In general, adverse events reported by INTELENCE  (r)  -treated subjects with hepatitis B and/or hepatitis C virus co-infection were similar to INTELENCE  (r)  -treated subjects without hepatitis B and/or hepatitis C virus co-infection.



   6.2 Clinical Trials Experience: Pediatric Subjects (6 years to less than 18 years of age)

  The safety assessment in children and adolescents is based on the Week 24 analysis of the single-arm, Phase 2 trial TMC125-C213 in which 101 antiretroviral treatment-experienced HIV-1 infected subjects 6 years to less than 18 years of age and weighing at least 16 kg received INTELENCE  (r)  in combination with other antiretroviral agents [  see      Clinical Studies (14.2)    ]. The frequency, type and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects. The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea. Rash was reported more frequently in female subjects than in male subjects (rash &gt;= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males). Rash (greater than or equal to Grade 2) occurred in 15% of pediatric subjects. In the majority of cases, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy. Rash was self-limiting and generally resolved within 1 week on continued therapy. The safety profile for subjects who completed 48 weeks of treatment was similar to the safety profile for subjects who completed 24 weeks of treatment.



   6.3 Postmarketing Experience

  The following events have been identified during postmarketing use of INTELENCE  (r)  . Because these events are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.



   Immune System Disorders  : Severe hypersensitivity reactions including DRESS and cases of hepatic failure have been reported [  see  Warnings and Precautions (5.1)    ].



   Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis



   Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].
</Section>
    <Section name="warnings and precautions" id="S2">    5 WARNINGS AND PRECAUTIONS



  EXCERPT:   Severe, potentially life threatening and fatal skin reactions have been reported. This includes cases of Stevens-Johnson syndrome, hypersensitivity reaction, toxic epidermal necrolysis and erythema multiforme. Immediately discontinue treatment if severe hypersensitivity, severe rash or rash with systemic symptoms or liver transaminase elevations develops and monitor clinical status, including liver transaminases closely. (  5.1  )



 



   5.1 Severe Skin and Hypersensitivity Reactions



  Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure. In Phase 3 clinical trials, Grade 3 and 4 rashes were reported in 1.3% of subjects receiving INTELENCE  (r)  compared to 0.2% of placebo subjects. A total of 2.2% of HIV-1-infected subjects receiving INTELENCE  (r)  discontinued from Phase 3 trials due to rash [ see  Adverse Reactions (6)    ]. Rash occurred most commonly during the first 6 weeks of therapy. The incidence of rash was higher in females [ see  Adverse Reactions (6)    ]



 Discontinue INTELENCE  (r)  immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema). Clinical status including liver transaminases should be monitored and appropriate therapy initiated. Delay in stopping INTELENCE  (r)  treatment after the onset of severe rash may result in a life-threatening reaction.



    5.2 Fat Redistribution



  Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.



    5.3 Immune Reconstitution Syndrome



  Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including INTELENCE  (r)  . During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.



 Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.
</Section>
  </Text>
  <Mentions>
    <Mention id="M1" section="S1" type="Severity" start="117" len="6" str="Severe" />
    <Mention id="M2" section="S1" type="AdverseReaction" start="124,150" len="4,9" str="skin reactions" />
    <Mention id="M3" section="S1" type="AdverseReaction" start="133" len="26" str="hypersensitivity reactions" />
    <Mention id="M4" section="S1" type="Severity" start="263" len="8" str="moderate" />
    <Mention id="M5" section="S1" type="Severity" start="263" len="18" str="moderate to severe" />
    <Mention id="M6" section="S1" type="Severity" start="275" len="6" str="severe" />
    <Mention id="M7" section="S1" type="AdverseReaction" start="365" len="4" str="rash" />
    <Mention id="M8" section="S1" type="AdverseReaction" start="374" len="21" str="peripheral neuropathy" />
    <Mention id="M9" section="S1" type="AdverseReaction" start="491" len="4" str="rash" />
    <Mention id="M10" section="S1" type="AdverseReaction" start="500" len="8" str="diarrhea" />
    <Mention id="M11" section="S1" type="Severity" start="1582" len="7" str="Grade 2" />
    <Mention id="M12" section="S1" type="AdverseReaction" start="1606" len="4" str="rash" />
    <Mention id="M13" section="S1" type="AdverseReaction" start="1620" len="24" str="Stevens-Johnson syndrome" />
    <Mention id="M14" section="S1" type="AdverseReaction" start="1651" len="16" str="hypersensitivity" />
    <Mention id="M15" section="S1" type="AdverseReaction" start="1681" len="19" str="erythema multiforme" />
    <Mention id="M16" section="S1" type="AdverseReaction" start="1946" len="4" str="rash" />
    <Mention id="M17" section="S1" type="AdverseReaction" start="1984" len="4" str="rash" />
    <Mention id="M18" section="S1" type="Severity" start="1993" len="4" str="mild" />
    <Mention id="M19" section="S1" type="Severity" start="1993" len="16" str="mild to moderate" />
    <Mention id="M20" section="S1" type="Severity" start="2001" len="8" str="moderate" />
    <Mention id="M21" section="S1" type="AdverseReaction" start="2094" len="4" str="Rash" />
    <Mention id="M22" section="S1" type="AdverseReaction" start="2177" len="4" str="rash" />
    <Mention id="M23" section="S1" type="AdverseReaction" start="2268" len="4" str="rash" />
    <Mention id="M24" section="S1" type="Severity" start="2276" len="7" str="Grade 2" />
    <Mention id="M25" section="S1" type="AdverseReaction" start="2369" len="4" str="rash" />
    <Mention id="M26" section="S1" type="DrugClass" start="2507" len="5" str="NNRTI" />
    <Mention id="M27" section="S1" type="AdverseReaction" start="2521" len="4" str="rash" />
    <Mention id="M28" section="S1" type="AdverseReaction" start="2613" len="4" str="rash" />
    <Mention id="M29" section="S1" type="DrugClass" start="2660" len="5" str="NNRTI" />
    <Mention id="M30" section="S1" type="AdverseReaction" start="2674" len="4" str="rash" />
    <Mention id="M31" section="S1" type="AdverseReaction" start="3835" len="21" str="Peripheral neuropathy" />
    <Mention id="M32" section="S1" type="AdverseReaction" start="4029" len="4" str="Rash" />
    <Mention id="M33" section="S1" type="AdverseReaction" start="4415" len="21" str="myocardial infarction" />
    <Mention id="M34" section="S1" type="AdverseReaction" start="4438" len="15" str="angina pectoris" />
    <Mention id="M35" section="S1" type="AdverseReaction" start="4455" len="19" str="atrial fibrillation" />
    <Mention id="M36" section="S1" type="AdverseReaction" start="4512" len="7" str="vertigo" />
    <Mention id="M37" section="S1" type="AdverseReaction" start="4543" len="14" str="blurred vision" />
    <Mention id="M38" section="S1" type="AdverseReaction" start="4594" len="31" str="gastroesophageal reflux disease" />
    <Mention id="M39" section="S1" type="AdverseReaction" start="4627" len="10" str="flatulence" />
    <Mention id="M40" section="S1" type="AdverseReaction" start="4639" len="9" str="gastritis" />
    <Mention id="M41" section="S1" type="AdverseReaction" start="4650" len="20" str="abdominal distension" />
    <Mention id="M42" section="S1" type="AdverseReaction" start="4672" len="12" str="pancreatitis" />
    <Mention id="M43" section="S1" type="AdverseReaction" start="4686" len="12" str="constipation" />
    <Mention id="M44" section="S1" type="AdverseReaction" start="4700" len="9" str="dry mouth" />
    <Mention id="M45" section="S1" type="AdverseReaction" start="4711" len="11" str="hematemesis" />
    <Mention id="M46" section="S1" type="AdverseReaction" start="4724" len="8" str="retching" />
    <Mention id="M47" section="S1" type="AdverseReaction" start="4734" len="10" str="stomatitis" />
    <Mention id="M48" section="S1" type="AdverseReaction" start="4807" len="12" str="sluggishness" />
    <Mention id="M49" section="S1" type="AdverseReaction" start="4851" len="16" str="hemolytic anemia" />
    <Mention id="M50" section="S1" type="AdverseReaction" start="4901" len="15" str="hepatic failure" />
    <Mention id="M51" section="S1" type="AdverseReaction" start="4918" len="12" str="hepatomegaly" />
    <Mention id="M52" section="S1" type="AdverseReaction" start="4932" len="19" str="cytolytic hepatitis" />
    <Mention id="M53" section="S1" type="AdverseReaction" start="4953" len="17" str="hepatic steatosis" />
    <Mention id="M54" section="S1" type="AdverseReaction" start="4972" len="9" str="hepatitis" />
    <Mention id="M55" section="S1" type="AdverseReaction" start="5015" len="21" str="drug hypersensitivity" />
    <Mention id="M56" section="S1" type="AdverseReaction" start="5038" len="30" str="immune reconstitution syndrome" />
    <Mention id="M57" section="S1" type="AdverseReaction" start="5113" len="17" str="diabetes mellitus" />
    <Mention id="M58" section="S1" type="AdverseReaction" start="5132" len="8" str="anorexia" />
    <Mention id="M59" section="S1" type="AdverseReaction" start="5142" len="12" str="dyslipidemia" />
    <Mention id="M60" section="S1" type="AdverseReaction" start="5189" len="12" str="paraesthesia" />
    <Mention id="M61" section="S1" type="AdverseReaction" start="5203" len="10" str="somnolence" />
    <Mention id="M62" section="S1" type="AdverseReaction" start="5215" len="10" str="convulsion" />
    <Mention id="M63" section="S1" type="AdverseReaction" start="5227" len="12" str="hypoesthesia" />
    <Mention id="M64" section="S1" type="AdverseReaction" start="5241" len="7" str="amnesia" />
    <Mention id="M65" section="S1" type="AdverseReaction" start="5250" len="7" str="syncope" />
    <Mention id="M66" section="S1" type="AdverseReaction" start="5259" len="24" str="disturbance in attention" />
    <Mention id="M67" section="S1" type="AdverseReaction" start="5285" len="11" str="hypersomnia" />
    <Mention id="M68" section="S1" type="AdverseReaction" start="5298" len="6" str="tremor" />
    <Mention id="M69" section="S1" type="AdverseReaction" start="5336" len="7" str="anxiety" />
    <Mention id="M70" section="S1" type="AdverseReaction" start="5345" len="15" str="sleep disorders" />
    <Mention id="M71" section="S1" type="AdverseReaction" start="5362" len="15" str="abnormal dreams" />
    <Mention id="M72" section="S1" type="AdverseReaction" start="5379" len="17" str="confusional state" />
    <Mention id="M73" section="S1" type="AdverseReaction" start="5398" len="14" str="disorientation" />
    <Mention id="M74" section="S1" type="AdverseReaction" start="5414" len="11" str="nervousness" />
    <Mention id="M75" section="S1" type="AdverseReaction" start="5427" len="10" str="nightmares" />
    <Mention id="M76" section="S1" type="AdverseReaction" start="5474" len="19" str="acute renal failure" />
    <Mention id="M77" section="S1" type="AdverseReaction" start="5544" len="12" str="gynecomastia" />
    <Mention id="M78" section="S1" type="AdverseReaction" start="5544" len="12" str="gynecomastia" />
    <Mention id="M79" section="S1" type="AdverseReaction" start="5613" len="18" str="exertional dyspnea" />
    <Mention id="M80" section="S1" type="AdverseReaction" start="5633" len="12" str="bronchospasm" />
    <Mention id="M81" section="S1" type="AdverseReaction" start="5694" len="12" str="night sweats" />
    <Mention id="M82" section="S1" type="AdverseReaction" start="5708" len="15" str="lipohypertrophy" />
    <Mention id="M83" section="S1" type="AdverseReaction" start="5725" len="7" str="prurigo" />
    <Mention id="M84" section="S1" type="AdverseReaction" start="5734" len="13" str="hyperhidrosis" />
    <Mention id="M85" section="S1" type="AdverseReaction" start="5749" len="8" str="dry skin" />
    <Mention id="M86" section="S1" type="AdverseReaction" start="5759" len="13" str="swelling face" />
    <Mention id="M87" section="S1" type="AdverseReaction" start="5854" len="22" str="acquired lipodystrophy" />
    <Mention id="M88" section="S1" type="AdverseReaction" start="5878" len="19" str="angioneurotic edema" />
    <Mention id="M89" section="S1" type="AdverseReaction" start="5899" len="19" str="erythema multiforme" />
    <Mention id="M90" section="S1" type="AdverseReaction" start="5923" len="19" str="haemorrhagic stroke" />
    <Mention id="M91" section="S1" type="AdverseReaction" start="8183" len="20" str="Decreased hemoglobin" />
    <Mention id="M92" section="S1" type="AdverseReaction" start="11208" len="23" str="Elevated glucose levels" />
    <Mention id="M93" section="S1" type="AdverseReaction" start="12929,12941" len="3,13" str="AST abnormalities" />
    <Mention id="M94" section="S1" type="AdverseReaction" start="12937" len="17" str="ALT abnormalities" />
    <Mention id="M95" section="S1" type="Severity" start="13068" len="7" str="Grade 2" />
    <Mention id="M96" section="S1" type="AdverseReaction" start="13097,13152" len="13,6" str="abnormalities of AST" />
    <Mention id="M97" section="S1" type="AdverseReaction" start="13097,13152,13160" len="13,2,3" str="abnormalities of ALT" />
    <Mention id="M98" section="S1" type="AdverseReaction" start="13097,13152,13167" len="13,2,15" str="abnormalities of total bilirubin" />
    <Mention id="M99" section="S1" type="AdverseReaction" start="14232" len="4" str="rash" />
    <Mention id="M100" section="S1" type="AdverseReaction" start="14376" len="4" str="rash" />
    <Mention id="M101" section="S1" type="AdverseReaction" start="14385" len="8" str="diarrhea" />
    <Mention id="M102" section="S1" type="AdverseReaction" start="14395" len="4" str="Rash" />
    <Mention id="M103" section="S1" type="AdverseReaction" start="14471" len="4" str="rash" />
    <Mention id="M104" section="S1" type="Severity" start="14479" len="7" str="Grade 2" />
    <Mention id="M105" section="S1" type="AdverseReaction" start="14575" len="4" str="rash" />
    <Mention id="M106" section="S1" type="AdverseReaction" start="14642" len="4" str="Rash" />
    <Mention id="M107" section="S1" type="Severity" start="14673" len="7" str="Grade 2" />
    <Mention id="M108" section="S1" type="AdverseReaction" start="14747" len="4" str="rash" />
    <Mention id="M109" section="S1" type="AdverseReaction" start="14747,14777" len="4,7" str="rash macular" />
    <Mention id="M110" section="S1" type="AdverseReaction" start="14747,14785" len="4,7" str="rash papular" />
    <Mention id="M111" section="S1" type="Severity" start="14756" len="4" str="mild" />
    <Mention id="M112" section="S1" type="Severity" start="14756" len="16" str="mild to moderate" />
    <Mention id="M113" section="S1" type="Severity" start="14764" len="8" str="moderate" />
    <Mention id="M114" section="S1" type="AdverseReaction" start="14843" len="4" str="Rash" />
    <Mention id="M115" section="S1" type="Severity" start="15433" len="6" str="Severe" />
    <Mention id="M116" section="S1" type="AdverseReaction" start="15440" len="16" str="hypersensitivity" />
    <Mention id="M117" section="S1" type="AdverseReaction" start="15477" len="5" str="DRESS" />
    <Mention id="M118" section="S1" type="AdverseReaction" start="15496" len="15" str="hepatic failure" />
    <Mention id="M119" section="S1" type="AdverseReaction" start="15633" len="14" str="rhabdomyolysis" />
    <Mention id="M120" section="S1" type="AdverseReaction" start="15696" len="5" str="Fatal" />
    <Mention id="M121" section="S1" type="AdverseReaction" start="15711" len="26" str="toxic epidermal necrolysis" />
    <Mention id="M122" section="S2" type="Severity" start="47" len="6" str="Severe" />
    <Mention id="M123" section="S2" type="Severity" start="67" len="16" str="life threatening" />
    <Mention id="M124" section="S2" type="AdverseReaction" start="88" len="5" str="fatal" />
    <Mention id="M125" section="S2" type="AdverseReaction" start="94" len="14" str="skin reactions" />
    <Mention id="M126" section="S2" type="AdverseReaction" start="152" len="24" str="Stevens-Johnson syndrome" />
    <Mention id="M127" section="S2" type="AdverseReaction" start="178" len="25" str="hypersensitivity reaction" />
    <Mention id="M128" section="S2" type="AdverseReaction" start="205" len="26" str="toxic epidermal necrolysis" />
    <Mention id="M129" section="S2" type="AdverseReaction" start="236" len="19" str="erythema multiforme" />
    <Mention id="M130" section="S2" type="Severity" start="545" len="6" str="Severe" />
    <Mention id="M131" section="S2" type="Factor" start="553" len="11" str="potentially" />
    <Mention id="M132" section="S2" type="Severity" start="565" len="16" str="life-threatening" />
    <Mention id="M133" section="S2" type="AdverseReaction" start="587" len="5" str="fatal" />
    <Mention id="M134" section="S2" type="AdverseReaction" start="593" len="14" str="skin reactions" />
    <Mention id="M135" section="S2" type="AdverseReaction" start="651" len="24" str="Stevens-Johnson syndrome" />
    <Mention id="M136" section="S2" type="AdverseReaction" start="677" len="26" str="toxic epidermal necrolysis" />
    <Mention id="M137" section="S2" type="AdverseReaction" start="708" len="19" str="erythema multiforme" />
    <Mention id="M138" section="S2" type="AdverseReaction" start="729" len="26" str="Hypersensitivity reactions" />
    <Mention id="M139" section="S2" type="AdverseReaction" start="766" len="49" str="Drug Rash with Eosinophilia and Systemic Symptoms" />
    <Mention id="M140" section="S2" type="AdverseReaction" start="817" len="5" str="DRESS" />
    <Mention id="M141" section="S2" type="AdverseReaction" start="874" len="4" str="rash" />
    <Mention id="M142" section="S2" type="AdverseReaction" start="919" len="17" str="organ dysfunction" />
    <Mention id="M143" section="S2" type="AdverseReaction" start="948" len="15" str="hepatic failure" />
    <Mention id="M144" section="S2" type="Severity" start="993" len="7" str="Grade 3" />
    <Mention id="M145" section="S2" type="Severity" start="993,1005" len="5,1" str="Grade 4" />
    <Mention id="M146" section="S2" type="AdverseReaction" start="1007" len="6" str="rashes" />
    <Mention id="M147" section="S2" type="AdverseReaction" start="1221" len="4" str="rash" />
    <Mention id="M148" section="S2" type="AdverseReaction" start="1261" len="4" str="Rash" />
    <Mention id="M149" section="S2" type="AdverseReaction" start="1343" len="4" str="rash" />
    <Mention id="M150" section="S2" type="AdverseReaction" start="2001,2029" len="14,11" str="Redistribution of body fat" />
    <Mention id="M151" section="S2" type="AdverseReaction" start="2016" len="24" str="accumulation of body fat" />
    <Mention id="M152" section="S2" type="AdverseReaction" start="2032,2115" len="8,18" str="body fat peripheral wasting" />
    <Mention id="M153" section="S2" type="AdverseReaction" start="2052" len="15" str="central obesity" />
    <Mention id="M154" section="S2" type="AdverseReaction" start="2069" len="29" str="dorsocervical fat enlargement" />
    <Mention id="M155" section="S2" type="AdverseReaction" start="2100" len="12" str="buffalo hump" />
    <Mention id="M156" section="S2" type="AdverseReaction" start="2135" len="14" str="facial wasting" />
    <Mention id="M157" section="S2" type="AdverseReaction" start="2151" len="18" str="breast enlargement" />
    <Mention id="M158" section="S2" type="AdverseReaction" start="2176" len="21" str="cushingoid appearance" />
    <Mention id="M159" section="S2" type="AdverseReaction" start="2439" len="30" str="Immune reconstitution syndrome" />
    <Mention id="M160" section="S2" type="DrugClass" start="2525" len="14" str="antiretroviral" />
    <Mention id="M161" section="S2" type="AdverseReaction" start="2696" len="21" str="inflammatory response" />
    <Mention id="M162" section="S2" type="AdverseReaction" start="2742" len="24" str="opportunistic infections" />
    <Mention id="M163" section="S2" type="AdverseReaction" start="2776" len="30" str="Mycobacterium avium infection" />
    <Mention id="M164" section="S2" type="AdverseReaction" start="2808" len="15" str="cytomegalovirus" />
    <Mention id="M165" section="S2" type="AdverseReaction" start="2825" len="32" str="Pneumocystis jiroveci pneumonia" />
    <Mention id="M166" section="S2" type="AdverseReaction" start="2859" len="3" str="PCP" />
    <Mention id="M167" section="S2" type="AdverseReaction" start="2867" len="12" str="tuberculosis" />
    <Mention id="M168" section="S2" type="AdverseReaction" start="2942" len="20" str="Autoimmune disorders" />
    <Mention id="M169" section="S2" type="AdverseReaction" start="2972" len="15" str="Graves' disease" />
    <Mention id="M170" section="S2" type="AdverseReaction" start="2989" len="12" str="polymyositis" />
    <Mention id="M171" section="S2" type="AdverseReaction" start="3007" len="23" str="Guillain-Barre syndrome" />
  </Mentions>
  <Relations>
    <Relation id="RL1" type="Effect" arg1="M2" arg2="M1" />
    <Relation id="RL2" type="Effect" arg1="M3" arg2="M1" />
    <Relation id="RL3" type="Effect" arg1="M7" arg2="M4" />
    <Relation id="RL4" type="Effect" arg1="M7" arg2="M5" />
    <Relation id="RL5" type="Effect" arg1="M7" arg2="M6" />
    <Relation id="RL6" type="Effect" arg1="M8" arg2="M4" />
    <Relation id="RL7" type="Effect" arg1="M8" arg2="M5" />
    <Relation id="RL8" type="Effect" arg1="M8" arg2="M6" />
    <Relation id="RL9" type="Effect" arg1="M12" arg2="M11" />
    <Relation id="RL10" type="Effect" arg1="M17" arg2="M18" />
    <Relation id="RL11" type="Effect" arg1="M17" arg2="M19" />
    <Relation id="RL12" type="Effect" arg1="M17" arg2="M20" />
    <Relation id="RL13" type="Effect" arg1="M23" arg2="M24" />
    <Relation id="RL14" type="Hypothetical" arg1="M27" arg2="M26" />
    <Relation id="RL15" type="Hypothetical" arg1="M30" arg2="M29" />
    <Relation id="RL16" type="Effect" arg1="M96" arg2="M95" />
    <Relation id="RL17" type="Effect" arg1="M97" arg2="M95" />
    <Relation id="RL18" type="Effect" arg1="M98" arg2="M95" />
    <Relation id="RL19" type="Effect" arg1="M103" arg2="M104" />
    <Relation id="RL20" type="Effect" arg1="M106" arg2="M107" />
    <Relation id="RL21" type="Effect" arg1="M108" arg2="M111" />
    <Relation id="RL22" type="Effect" arg1="M108" arg2="M112" />
    <Relation id="RL23" type="Effect" arg1="M108" arg2="M113" />
    <Relation id="RL24" type="Effect" arg1="M116" arg2="M115" />
    <Relation id="RL25" type="Effect" arg1="M125" arg2="M122" />
    <Relation id="RL26" type="Effect" arg1="M125" arg2="M123" />
    <Relation id="RL27" type="Effect" arg1="M134" arg2="M130" />
    <Relation id="RL28" type="Effect" arg1="M134" arg2="M132" />
    <Relation id="RL29" type="Hypothetical" arg1="M134" arg2="M131" />
    <Relation id="RL30" type="Effect" arg1="M146" arg2="M145" />
    <Relation id="RL31" type="Effect" arg1="M146" arg2="M144" />
    <Relation id="RL32" type="Hypothetical" arg1="M159" arg2="M160" />
  </Relations>
  <Reactions>
    <Reaction id="AR1" str="skin reactions">
      <Normalization id="AR1.N1" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
    </Reaction>
    <Reaction id="AR2" str="hypersensitivity reactions">
      <Normalization id="AR2.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" meddra_llt="Hypersensitivity reaction" meddra_llt_id="10020756" />
    </Reaction>
    <Reaction id="AR3" str="rash">
      <Normalization id="AR3.N1" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Reaction>
    <Reaction id="AR4" str="peripheral neuropathy">
      <Normalization id="AR4.N1" meddra_pt="Neuropathy peripheral" meddra_pt_id="10029331" />
    </Reaction>
    <Reaction id="AR5" str="diarrhea">
      <Normalization id="AR5.N1" meddra_pt="Diarrhoea" meddra_pt_id="10012735" meddra_llt="Diarrhea" meddra_llt_id="10012727" />
    </Reaction>
    <Reaction id="AR6" str="stevens-johnson syndrome">
      <Normalization id="AR6.N1" meddra_pt="Stevens-Johnson syndrome" meddra_pt_id="10042033" />
    </Reaction>
    <Reaction id="AR7" str="hypersensitivity">
      <Normalization id="AR7.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Reaction>
    <Reaction id="AR8" str="erythema multiforme">
      <Normalization id="AR8.N1" meddra_pt="Erythema multiforme" meddra_pt_id="10015218" />
    </Reaction>
    <Reaction id="AR9" str="myocardial infarction">
      <Normalization id="AR9.N1" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Reaction>
    <Reaction id="AR10" str="angina pectoris">
      <Normalization id="AR10.N1" meddra_pt="Angina pectoris" meddra_pt_id="10002383" />
    </Reaction>
    <Reaction id="AR11" str="atrial fibrillation">
      <Normalization id="AR11.N1" meddra_pt="Atrial fibrillation" meddra_pt_id="10003658" />
    </Reaction>
    <Reaction id="AR12" str="vertigo">
      <Normalization id="AR12.N1" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Reaction>
    <Reaction id="AR13" str="blurred vision">
      <Normalization id="AR13.N1" meddra_pt="Vision blurred" meddra_pt_id="10047513" meddra_llt="Blurred vision" meddra_llt_id="10005886" />
    </Reaction>
    <Reaction id="AR14" str="gastroesophageal reflux disease">
      <Normalization id="AR14.N1" meddra_pt="Gastrooesophageal reflux disease" meddra_pt_id="10017885" meddra_llt="Gastroesophageal reflux disease" meddra_llt_id="10066874" />
    </Reaction>
    <Reaction id="AR15" str="flatulence">
      <Normalization id="AR15.N1" meddra_pt="Flatulence" meddra_pt_id="10016766" />
    </Reaction>
    <Reaction id="AR16" str="gastritis">
      <Normalization id="AR16.N1" meddra_pt="Gastritis" meddra_pt_id="10017853" />
    </Reaction>
    <Reaction id="AR17" str="abdominal distension">
      <Normalization id="AR17.N1" meddra_pt="Abdominal distension" meddra_pt_id="10000060" />
    </Reaction>
    <Reaction id="AR18" str="pancreatitis">
      <Normalization id="AR18.N1" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Reaction>
    <Reaction id="AR19" str="constipation">
      <Normalization id="AR19.N1" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Reaction>
    <Reaction id="AR20" str="dry mouth">
      <Normalization id="AR20.N1" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Reaction>
    <Reaction id="AR21" str="hematemesis">
      <Normalization id="AR21.N1" meddra_pt="Haematemesis" meddra_pt_id="10018830" meddra_llt="Hematemesis" meddra_llt_id="10019418" />
    </Reaction>
    <Reaction id="AR22" str="retching">
      <Normalization id="AR22.N1" meddra_pt="Retching" meddra_pt_id="10038776" />
    </Reaction>
    <Reaction id="AR23" str="stomatitis">
      <Normalization id="AR23.N1" meddra_pt="Stomatitis" meddra_pt_id="10042128" />
    </Reaction>
    <Reaction id="AR24" str="sluggishness">
      <Normalization id="AR24.N1" meddra_pt="Sluggishness" meddra_pt_id="10041052" />
    </Reaction>
    <Reaction id="AR25" str="hemolytic anemia">
      <Normalization id="AR25.N1" meddra_pt="Haemolytic anaemia" meddra_pt_id="10018916" meddra_llt="Hemolytic anemia" meddra_llt_id="10019493" />
    </Reaction>
    <Reaction id="AR26" str="hepatic failure">
      <Normalization id="AR26.N1" meddra_pt="Hepatic failure" meddra_pt_id="10019663" />
    </Reaction>
    <Reaction id="AR27" str="hepatomegaly">
      <Normalization id="AR27.N1" meddra_pt="Hepatomegaly" meddra_pt_id="10019842" />
    </Reaction>
    <Reaction id="AR28" str="cytolytic hepatitis">
      <Normalization id="AR28.N1" meddra_pt="Hepatitis" meddra_pt_id="10019717" meddra_llt="Cytolytic hepatitis" meddra_llt_id="10050904" />
    </Reaction>
    <Reaction id="AR29" str="hepatic steatosis">
      <Normalization id="AR29.N1" meddra_pt="Hepatic steatosis" meddra_pt_id="10019708" />
    </Reaction>
    <Reaction id="AR30" str="hepatitis">
      <Normalization id="AR30.N1" meddra_pt="Hepatitis" meddra_pt_id="10019717" />
    </Reaction>
    <Reaction id="AR31" str="drug hypersensitivity">
      <Normalization id="AR31.N1" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
    </Reaction>
    <Reaction id="AR32" str="immune reconstitution syndrome">
      <Normalization id="AR32.N1" meddra_pt="Immune reconstitution inflammatory syndrome" meddra_pt_id="10065042" meddra_llt="Immune reconstitution syndrome" meddra_llt_id="10054014" />
    </Reaction>
    <Reaction id="AR33" str="diabetes mellitus">
      <Normalization id="AR33.N1" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Reaction>
    <Reaction id="AR34" str="anorexia">
      <Normalization id="AR34.N1" meddra_pt="Decreased appetite" meddra_pt_id="10061428" meddra_llt="Anorexia" meddra_llt_id="10002646" />
    </Reaction>
    <Reaction id="AR35" str="dyslipidemia">
      <Normalization id="AR35.N1" meddra_pt="Dyslipidaemia" meddra_pt_id="10058108" meddra_llt="Dyslipidemia" meddra_llt_id="10058110" />
    </Reaction>
    <Reaction id="AR36" str="paraesthesia">
      <Normalization id="AR36.N1" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Reaction>
    <Reaction id="AR37" str="somnolence">
      <Normalization id="AR37.N1" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Reaction>
    <Reaction id="AR38" str="convulsion">
      <Normalization id="AR38.N1" meddra_pt="Seizure" meddra_pt_id="10039906" meddra_llt="Convulsion" meddra_llt_id="10010904" />
    </Reaction>
    <Reaction id="AR39" str="hypoesthesia">
      <Normalization id="AR39.N1" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" meddra_llt="Hypoesthesia" meddra_llt_id="10020976" />
    </Reaction>
    <Reaction id="AR40" str="amnesia">
      <Normalization id="AR40.N1" meddra_pt="Amnesia" meddra_pt_id="10001949" />
    </Reaction>
    <Reaction id="AR41" str="syncope">
      <Normalization id="AR41.N1" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Reaction>
    <Reaction id="AR42" str="disturbance in attention">
      <Normalization id="AR42.N1" meddra_pt="Disturbance in attention" meddra_pt_id="10013496" />
    </Reaction>
    <Reaction id="AR43" str="hypersomnia">
      <Normalization id="AR43.N1" meddra_pt="Hypersomnia" meddra_pt_id="10020765" />
    </Reaction>
    <Reaction id="AR44" str="tremor">
      <Normalization id="AR44.N1" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Reaction>
    <Reaction id="AR45" str="anxiety">
      <Normalization id="AR45.N1" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Reaction>
    <Reaction id="AR46" str="sleep disorders">
      <Normalization id="AR46.N1" meddra_pt="Sleep disorder" meddra_pt_id="10040984" />
    </Reaction>
    <Reaction id="AR47" str="abnormal dreams">
      <Normalization id="AR47.N1" meddra_pt="Abnormal dreams" meddra_pt_id="10000125" />
    </Reaction>
    <Reaction id="AR48" str="confusional state">
      <Normalization id="AR48.N1" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Reaction>
    <Reaction id="AR49" str="disorientation">
      <Normalization id="AR49.N1" meddra_pt="Disorientation" meddra_pt_id="10013395" />
    </Reaction>
    <Reaction id="AR50" str="nervousness">
      <Normalization id="AR50.N1" meddra_pt="Nervousness" meddra_pt_id="10029216" />
    </Reaction>
    <Reaction id="AR51" str="nightmares">
      <Normalization id="AR51.N1" meddra_pt="Nightmare" meddra_pt_id="10029412" meddra_llt="Nightmares" meddra_llt_id="10029414" />
    </Reaction>
    <Reaction id="AR52" str="acute renal failure">
      <Normalization id="AR52.N1" meddra_pt="Acute kidney injury" meddra_pt_id="10069339" meddra_llt="Acute renal failure" meddra_llt_id="10001041" />
    </Reaction>
    <Reaction id="AR53" str="gynecomastia">
      <Normalization id="AR53.N1" meddra_pt="Gynaecomastia" meddra_pt_id="10018800" meddra_llt="Gynecomastia" meddra_llt_id="10018801" />
    </Reaction>
    <Reaction id="AR54" str="exertional dyspnea">
      <Normalization id="AR54.N1" meddra_pt="Dyspnoea exertional" meddra_pt_id="10013971" meddra_llt="Exertional dyspnea" meddra_llt_id="10055548" />
    </Reaction>
    <Reaction id="AR55" str="bronchospasm">
      <Normalization id="AR55.N1" meddra_pt="Bronchospasm" meddra_pt_id="10006482" />
    </Reaction>
    <Reaction id="AR56" str="night sweats">
      <Normalization id="AR56.N1" meddra_pt="Night sweats" meddra_pt_id="10029410" />
    </Reaction>
    <Reaction id="AR57" str="lipohypertrophy">
      <Normalization id="AR57.N1" meddra_pt="Lipohypertrophy" meddra_pt_id="10062315" />
    </Reaction>
    <Reaction id="AR58" str="prurigo">
      <Normalization id="AR58.N1" meddra_pt="Prurigo" meddra_pt_id="10037083" />
    </Reaction>
    <Reaction id="AR59" str="hyperhidrosis">
      <Normalization id="AR59.N1" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Reaction>
    <Reaction id="AR60" str="dry skin">
      <Normalization id="AR60.N1" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Reaction>
    <Reaction id="AR61" str="swelling face">
      <Normalization id="AR61.N1" meddra_pt="Swelling face" meddra_pt_id="10042682" />
    </Reaction>
    <Reaction id="AR62" str="acquired lipodystrophy">
      <Normalization id="AR62.N1" meddra_pt="Lipodystrophy acquired" meddra_pt_id="10049287" />
    </Reaction>
    <Reaction id="AR63" str="angioneurotic edema">
      <Normalization id="AR63.N1" meddra_pt="Angioedema" meddra_pt_id="10002424" meddra_llt="Angioneurotic edema" meddra_llt_id="10002471" />
    </Reaction>
    <Reaction id="AR64" str="haemorrhagic stroke">
      <Normalization id="AR64.N1" meddra_pt="Haemorrhagic stroke" meddra_pt_id="10019016" />
    </Reaction>
    <Reaction id="AR65" str="decreased hemoglobin">
      <Normalization id="AR65.N1" meddra_pt="Haemoglobin decreased" meddra_pt_id="10018884" meddra_llt="Decreased hemoglobin" meddra_llt_id="10011964" />
    </Reaction>
    <Reaction id="AR66" str="elevated glucose levels">
      <Normalization id="AR66.N1" meddra_pt="Blood glucose increased" meddra_pt_id="10005557" meddra_llt="Glucose increased" meddra_llt_id="10018421" />
    </Reaction>
    <Reaction id="AR67" str="ast abnormalities">
      <Normalization id="AR67.N1" meddra_pt="Aspartate aminotransferase abnormal" meddra_pt_id="10003477" />
    </Reaction>
    <Reaction id="AR68" str="alt abnormalities">
      <Normalization id="AR68.N1" meddra_pt="Alanine aminotransferase abnormal" meddra_pt_id="10001547" />
    </Reaction>
    <Reaction id="AR69" str="abnormalities of ast">
      <Normalization id="AR69.N1" meddra_pt="Aspartate aminotransferase abnormal" meddra_pt_id="10003477" />
    </Reaction>
    <Reaction id="AR70" str="abnormalities of alt">
      <Normalization id="AR70.N1" meddra_pt="Alanine aminotransferase abnormal" meddra_pt_id="10001547" />
    </Reaction>
    <Reaction id="AR71" str="abnormalities of total bilirubin">
      <Normalization id="AR71.N1" meddra_pt="Blood bilirubin abnormal" meddra_pt_id="10058477" meddra_llt="Bilirubin total abnormal" meddra_llt_id="10071561" />
    </Reaction>
    <Reaction id="AR72" str="rash macular">
      <Normalization id="AR72.N1" meddra_pt="Rash macular" meddra_pt_id="10037867" />
    </Reaction>
    <Reaction id="AR73" str="rash papular">
      <Normalization id="AR73.N1" meddra_pt="Rash papular" meddra_pt_id="10037876" />
    </Reaction>
    <Reaction id="AR74" str="dress">
      <Normalization id="AR74.N1" meddra_pt="Drug reaction with eosinophilia and systemic symptoms" meddra_pt_id="10073508" meddra_llt="DRESS syndrome" meddra_llt_id="10058899" />
    </Reaction>
    <Reaction id="AR75" str="rhabdomyolysis">
      <Normalization id="AR75.N1" meddra_pt="Rhabdomyolysis" meddra_pt_id="10039020" />
    </Reaction>
    <Reaction id="AR76" str="fatal">
      <Normalization id="AR76.N1" meddra_pt="Death" meddra_pt_id="10011906" />
    </Reaction>
    <Reaction id="AR77" str="toxic epidermal necrolysis">
      <Normalization id="AR77.N1" meddra_pt="Toxic epidermal necrolysis" meddra_pt_id="10044223" />
    </Reaction>
    <Reaction id="AR78" str="hypersensitivity reaction">
      <Normalization id="AR78.N1" meddra_pt="Hypersensitivity" meddra_pt_id="10020751" meddra_llt="Hypersensitivity reaction" meddra_llt_id="10020756" />
    </Reaction>
    <Reaction id="AR79" str="drug rash with eosinophilia and systemic symptoms">
      <Normalization id="AR79.N1" meddra_pt="Drug reaction with eosinophilia and systemic symptoms" meddra_pt_id="10073508" meddra_llt="Drug rash with eosinophilia and systemic symptoms" meddra_llt_id="10058919" />
    </Reaction>
    <Reaction id="AR80" str="organ dysfunction">
      <Normalization id="AR80.N1" meddra_pt="Organ failure" meddra_pt_id="10053159" />
    </Reaction>
    <Reaction id="AR81" str="rashes">
      <Normalization id="AR81.N1" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Reaction>
    <Reaction id="AR82" str="redistribution of body fat">
      <Normalization id="AR82.N1" meddra_pt="Fat redistribution" meddra_pt_id="10048474" />
    </Reaction>
    <Reaction id="AR83" str="accumulation of body fat">
      <Normalization id="AR83.N1" meddra_pt="Body fat disorder" meddra_pt_id="10055164" />
    </Reaction>
    <Reaction id="AR84" str="body fat peripheral wasting">
      <Normalization id="AR84.N1" meddra_pt="Lipoatrophy" meddra_pt_id="10024604" meddra_llt="Fat atrophy NOS" meddra_llt_id="10016242" />
    </Reaction>
    <Reaction id="AR85" str="central obesity">
      <Normalization id="AR85.N1" meddra_pt="Central obesity" meddra_pt_id="10065941" />
    </Reaction>
    <Reaction id="AR86" str="dorsocervical fat enlargement">
      <Normalization id="AR86.N1" meddra_pt="Lipohypertrophy" meddra_pt_id="10062315" meddra_llt="Buffalo hump" meddra_llt_id="10006539" />
    </Reaction>
    <Reaction id="AR87" str="buffalo hump">
      <Normalization id="AR87.N1" meddra_pt="Lipohypertrophy" meddra_pt_id="10062315" meddra_llt="Buffalo hump" meddra_llt_id="10006539" />
    </Reaction>
    <Reaction id="AR88" str="facial wasting">
      <Normalization id="AR88.N1" meddra_pt="Facial wasting" meddra_pt_id="10056866" />
    </Reaction>
    <Reaction id="AR89" str="breast enlargement">
      <Normalization id="AR89.N1" meddra_pt="Breast enlargement" meddra_pt_id="10006242" />
    </Reaction>
    <Reaction id="AR90" str="cushingoid appearance">
      <Normalization id="AR90.N1" meddra_pt="Cushingoid" meddra_pt_id="10011655" meddra_llt="Cushingoid facies" meddra_llt_id="10011656" />
    </Reaction>
    <Reaction id="AR91" str="inflammatory response">
      <Normalization id="AR91.N1" meddra_pt="Inflammation" meddra_pt_id="10061218" meddra_llt="Inflammatory reaction" meddra_llt_id="10021995" />
    </Reaction>
    <Reaction id="AR92" str="opportunistic infections">
      <Normalization id="AR92.N1" meddra_pt="Opportunistic infection" meddra_pt_id="10030901" />
    </Reaction>
    <Reaction id="AR93" str="mycobacterium avium infection">
      <Normalization id="AR93.N1" meddra_pt="Mycobacterium avium complex infection" meddra_pt_id="10058806" meddra_llt="Infection mycobacterium avium" meddra_llt_id="10021840" />
    </Reaction>
    <Reaction id="AR94" str="cytomegalovirus">
      <Normalization id="AR94.N1" meddra_pt="Cytomegalovirus infection" meddra_pt_id="10011831" />
    </Reaction>
    <Reaction id="AR95" str="pneumocystis jiroveci pneumonia">
      <Normalization id="AR95.N1" meddra_pt="Pneumocystis jirovecii pneumonia" meddra_pt_id="10073755" meddra_llt="Pneumocystis jiroveci pneumonia" meddra_llt_id="10064108" />
    </Reaction>
    <Reaction id="AR96" str="pcp">
      <Normalization id="AR96.N1" meddra_pt="Pneumocystis jirovecii pneumonia" meddra_pt_id="10073755" />
    </Reaction>
    <Reaction id="AR97" str="tuberculosis">
      <Normalization id="AR97.N1" meddra_pt="Tuberculosis" meddra_pt_id="10044755" />
    </Reaction>
    <Reaction id="AR98" str="autoimmune disorders">
      <Normalization id="AR98.N1" meddra_pt="Autoimmune disorder" meddra_pt_id="10061664" />
    </Reaction>
    <Reaction id="AR99" str="graves' disease">
      <Normalization id="AR99.N1" meddra_pt="Basedow's disease" meddra_pt_id="10004161" meddra_llt="Graves' disease" meddra_llt_id="10018706" />
    </Reaction>
    <Reaction id="AR100" str="polymyositis">
      <Normalization id="AR100.N1" meddra_pt="Polymyositis" meddra_pt_id="10036102" />
    </Reaction>
    <Reaction id="AR101" str="guillain-barre syndrome">
      <Normalization id="AR101.N1" meddra_pt="Guillain-Barre syndrome" meddra_pt_id="10018767" />
    </Reaction>
  </Reactions>
</Label>
